M&A Deal Summary |
|
|---|---|
| Date | 2021-08-26 |
| Target | Wavelength Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Seqens |
| Sellers(s) | SK Capital Partners |
| Deal Type | Merger |
SEARCH BY
Try For Free 7-Day Free Trial
Seqens is a global diversified chemicals Group that produces and distributes essential chemicals that are used in everyday products. Seqens offers a broad portfolio of active ingredients, pharmaceutical intermediates, and specialty ingredients, develops and industrializes the most demanding molecules, and relies on its ability to innovate, develop and implement the best available technologies. Seqens was founded in 2003 and is based in Ecully, France.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 5 |
| Sector (Life Science) | 2 of 2 |
| Type (Merger) | 1 of 1 |
| Country (Israel) | 1 of 1 |
| Year (2021) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-06-20 |
PCI Synthesis
Newburyport, Massachusetts, United States PCI Synthesis, Inc. is a Pharmaceutical Development CDMO (Contract Development and Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in the New England area. PCI Synthesis is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-09-07 |
PCAS
Longjumeau, France PCAS is an international fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. PCAS was founded in 1962 and is based in Longjumeau, France. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2007 |
| PE ASSETS | 4.9B USD |
| Size | Large |
| Type | Sector Agnostic |
SK Capital Partners is a private investor in mature and middle-market companies located throughout North America. SK Capital focuses on companies with opportunities for substantial business improvement and strong growth prospects. The Firm looks to invest $100 to $200 million of equity in transactions valued up to $500 million. Prospective businesses typically generate $50 to $500 million in revenues and at least $100 million in EBITDA. Areas of interest include specialty materials, chemicals and healthcare. The Firm will consider a variety of transaction situations, including buyouts, recapitalizations, growth equity financings, and corporate carve-outs. SK Capital Partners was spun out of Arsenal Capital Partners and became independent in 2007. SK Capital Partners is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 14 |
| Sector (Life Science) | 2 of 2 |
| Type (Merger) | 2 of 2 |
| Country (Israel) | 1 of 1 |
| Year (2021) | 3 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-08-23 |
Deltech - Monomers Polymers & European Businesses
Baton Rouge, Louisiana, United States Deltech's Monomers, Polymers & European Businesses provides the production of high-performance aromatic monomers and specialized crystal polystyrene. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-12-13 |
Tri-Tex
St-Eustache, Quebec, Canada Tri-Tex is a producer of high-performance specialty chemicals focused on the adhesive, sealants, surfactants, and textile & paper chemical markets. Tri-Tex was founded in 1882 and is headquartered in St-Eustache, Quebec. |
Sell | - |
